-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On the 5th, Genentech, a subsidiary of Roche, announced that the US FDA has approved the IL-6 receptor inhibitor Actemra (tocilizumab) to expand its indications for the reduction of systemic sclerosis (scleroderma) related interstitial diseases Lung disease (SSc-ILD) The rate of decline in lung function in adult patients.
Scleroderma is a rare disease that causes tissues throughout the body (including lungs and other organs) to thicken and form scar tissue.
Actemra is a humanized IL-6 receptor antagonist.
"We are very pleased to be able to provide the first FDA-approved biological treatment option for patients with SSc-ILD.
Reference materials:
[1] Genentech's Actemra Becomes the First Biologic Therapy Approved by the FDA for Slowing the Rate of Decline in Pulmonary Function in Adults With Systemic Sclerosis-Associated Interstitial Lung Disease, a Rare, Debilitating Condition.
